Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07253051

BRCA Mutation Carriers' Platform a Multicenter Study

BRCA Mutation Carriers' Platform, a Multicenter Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Subjects who carry mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 genes) are at higher risk of developing cancers. Despite the cumulative amount of evidence published in the literature in the last two decades, the management of BRCA mutation carriers is still not completely defined. Since the prevalence of the mutation is estimated to be 1:400 - 1:500 individuals, the total number of BRCA mutation carriers should be around 140.000 - 150.000 in the Italian population. It is estimated that 87% of women with BRCA mutations will experience, in their lifetime, a tumor with a genetic origin. About 20% of the 5200 ovarian cancer cases diagnosed each year in Italy has a genetic origin and could potentially be the object of primary prevention. To date, and to the best of our knowledge, a national prospective data collection on women with BRCA mutations has not been yet established.

Conditions

Interventions

TypeNameDescription
OTHERRegistration of clinical datas in the platformRegistration of clinical datas in the platform of female individual carrying a BRCA1 or BRCA2 mutation

Timeline

Start date
2025-04-05
Primary completion
2045-04-01
Completion
2045-12-31
First posted
2025-11-28
Last updated
2025-11-28

Locations

40 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT07253051. Inclusion in this directory is not an endorsement.